Rapidly Evolving Stem Cells Market Opens Up Doors for Related Research Tools, Says Frost & Sullivan

Informations

• Publié par: frost-sullivan
• Nombre de lectures: 6
• Langue: English

Extrait

Rapidly Evolving Stem Cells Market Opens Up

Doors for Related Research Tools, Says Frost

& Sullivan

PR Newswire

LONDON, May 30, 2012

- Lack of Venture Capital Infusions Threatens to Slow Pace of

Research and Market Development

LONDON

, May 30, 2012 /PRNewswire/ -- Stem cell research is very dynamic

with research trends, focus, and approaches evolving extremely rapidly. The

tool market has to quickly adapt to these challenges and develop innovative

tools that address and accelerate research accomplishments.

New analysis from Frost & Sullivan (http://www.drugdiscovery.frost.com),

Strategic Analysis of the European Stem Cell Research Tools Market

,

finds that the market earned revenues of

$148.4 million

in 2011 and estimates

this to reach

$322.0 million

in 2017. The segments covered include: bio-imaging

and microscopy, cell biology tools, immunochemical, molecular biology tools,

and protein biochemistry tools.

"Firms with the capacity to supply tools for stem cell research will increase as

the science matures," notes Frost & Sullivan Senior Research Analyst Divyaa

Ravishankar. "Soon demand and supply will achieve a degree of equilibrium."

Already, a sizeable stem cell research products market has emerged. Another

positive sign for the market has been enhanced industry- academic

collaboration.

A key step forward has been the stem cell regulations in a few countries

allowing the use of certain cell lines. In some countries such as

France

, for

instance, stem cell regulations are being renewed for the procurement and use

of stem cells.

"Such trends indicate the potential for a regulatory climate that would be far

less restrictive than the current scenario," adds Divyaa Ravishankar. "This,

together with the prospect of diverse applications within the healthcare arena,

is bolstering the future of the market."

However, the lack of venture capitalists (VC) poses a grave challenge. VC

funding is driven by investment concerns, with companies bidding to double

their money every few years in order to return revenue to the fund's investors.

As a high risk venture, stem cell technology does not exactly present an

attractive investment proposition.

"While these are financial concerns, from the technological standpoint, the

challenge remains to understand the basic biology behind stem cells," remarks

Divyaa Ravishankar. "There is an urgent need to design and develop specific

technology platforms that enhance the production, genetic stability and

integration of transplanted cells."

If you are interested in more information on this study, please send an e-mail

with your contact details to Janique Morvan, Corporate Communications, at

[e-mail].

Strategic Analysis of the European Stem Cell Research Tools Market

is

part of the

Clinical Diagnostics

Growth Partnership Services programme,